142 results
8-K
EX-2.1
RVLPQ
RVL Pharmaceuticals plc
27 Nov 23
Bankruptcy or Receivership
4:06pm
the Reorganized Debtors shall be responsible for any Professional Fees incurred after the Effective Date. The sole recourse of the Professionals with respect … any further action or order of the Bankruptcy Court or any other Entity. Neither the Debtors nor the Reorganized Debtors shall be responsible for any
8-K
EX-10.1
RVLPQ
RVL Pharmaceuticals plc
20 Oct 23
Entry into a Material Definitive Agreement
5:00pm
Financial Institution, a UK Resolution Authority.
“Responsible Financial Officer” means the chief executive officer, president, chief financial officer … hereunder that is signed by a Responsible Financial Officer of a Loan Party shall be conclusively presumed to have been authorized by all necessary corporate
8-K
RVLPQ
RVL Pharmaceuticals plc
13 Oct 23
Termination of a Material Definitive Agreement
4:15pm
://restructuring.ra.kroll.com/RVL. Interested parties who may have questions related to the Chapter 11 Cases may call the responsible claims agent
8-K
EX-99.1
RVLPQ
RVL Pharmaceuticals plc
13 Oct 23
Termination of a Material Definitive Agreement
4:15pm
be responsible for any Professional Fees incurred after the Effective Date. The sole recourse of the Professionals with respect to any such fees shall … , the Claims Register shall be closed and any party responsible for making distributions shall be authorized and entitled to recognize only those Holders
UPLOAD
RVLPQ
RVL Pharmaceuticals plc
24 Aug 23
Letter from SEC
12:00am
.
Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
that the company and its management are responsible
8-K
EX-4.1
n2myqfdb5 a6u
18 Aug 23
RVL Pharmaceuticals plc Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
4:06pm
8-K
EX-10.1
lrrlro7l2 ehb7dy
18 Aug 23
RVL Pharmaceuticals plc Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
4:06pm
8-K
EX-4.3
86zu0kua
18 Aug 23
RVL Pharmaceuticals plc Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
4:06pm
8-K
EX-4.2
57uky
18 Aug 23
RVL Pharmaceuticals plc Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
4:06pm
8-K
EX-4.4
s0dznab069qsxp3
18 Aug 23
RVL Pharmaceuticals plc Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
4:06pm
424B5
h0v342jv6sa kmhe
17 Aug 23
Prospectus supplement for primary offering
4:05pm
UPLOAD
uy86 coiaibfbq9i4jh
8 Aug 23
Letter from SEC
12:00am
CORRESP
whojtobj
27 Jul 23
Correspondence with SEC
12:00am
CORRESP
as48n 2e693x6iyqoyr
25 May 23
Correspondence with SEC
12:00am
UPLOAD
zzq6dm3jnqf1q1fpk
20 Apr 23
Letter from SEC
12:00am